Presently, 260 drug candidates are being evaluated in clinical / preclinical stages for the treatment of a wide variety of disease indications

The concept of microbiome-based therapeutics has generated significant enthusiasm within the medical science community, defining a new frontier in the field of medicine. Despite having captured the interest of several venture capital firms and big pharma players, no microbiome-based therapeutic has been officially approved by an authorized medical product regulator. However, the current development pipeline of microbiome therapeutics has several promising candidates that are likely to result in commercial success stories soon.

 

Key Inclusions

• A detailed assessment of the current market landscape of microbiome therapeutics, providing information on drug / therapy developer(s) (such as year of establishment, location of headquarters and company size), clinical study sponsor(s) or collaborators, phase of development (clinical, preclinical, and discovery stage) of product candidates, type of molecule (small molecule and biologic), type of therapy (prebiotic, probiotic, and prescription drug), target indication(s), key therapeutic area(s), molecular / biological target (if available), mechanism of action (if available), route of administration, type of drug formulation (tablet, capsule, gel, lotion, cream, ointment, nasal spray and 4+ categories), dosing frequency (reported for clinical candidates only), and information on special drug designations (if any). In addition, the chapter highlights the various technology platforms that are being actively used for the development of microbiome therapeutics.

 

• Elaborate profiles of key players (established after 2005) that are engaged in the development of microbiome therapeutics (which are presently in both preclinical and clinical stages of development); each profile features a brief overview of the company, its financial information (if available), microbiome-based product portfolio, information on advanced stage (phase II and above) pipeline candidates (featuring a drug overview, current status of development, clinical trial information, and clinical trial end-point analysis) and an informed future outlook.

 

A discussion on the various types of diagnostic tests, specifically highlighting the importance of next-generation sequencing within this field of research, along with [A] a detailed review of the current market landscape of microbiome diagnostic tests, including the information on the developer(s) (such as year of establishment, location of headquarters and company size), stage of development (commercialized and under development), type of sample used (blood, feces, saliva and vaginal swab), target indication(s), key therapeutic area(s), result turnaround time, and purpose of diagnosis, [B] brief profiles of popular diagnostic developers, and [C] an indicative list of screening and profiling test kits, including information on the developer(s) (such as year of establishment, location of headquarters and company size), type of sample used (blood, feces, saliva and vaginal swab), key therapeutic area(s), and result turnaround time

 

To order this 640+ page report, which features 235+ figures and 275+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/human-microbiome-market/281.html

 

The USD 4 billion (by 2030) financial opportunity within the microbiome therapeutics (Tx) market and diagnostics (Dx) markets, has been analyzed across the following segments:

§  Type of Therapy (Tx)

§  Prescription Drug

§  Prebiotics

§  Probiotics

 

§  Type of Molecule (Tx)

§  Small Molecules

§  Biologics

 

§  Target Indication (Tx+Dx)

§  Acne Vulgaris

§  Atopic Dermatitis

§  Clostridium difficile Infection

§  Colorectal Cancer

§  Crohn’s Disease

§  Diabetes

§  Irritable Bowel Syndrome

§  Lactose Intolerance

§  Lung Cancer

§  Nonalcoholic steatohepatitis (NASH)

§  Obesity

§  Ulcerative colitis

 

§  Therapeutic Area (Tx+Dx)

§  Autoimmune Disorders

§  Dental Disorders

§  Digestive and Gastrointestinal Disorders

§  Dermatological Disorders

§  Infectious Disease

§  Metabolic Disorders

§  Oncology

§  Others

 

§  Key Geographical Regions (Tx+Dx)

§  North America

§  Europe

§  Asia-Pacific and Rest of the World

 

 

The Human Microbiome Market, 2019-2030 report features the following companies, which we identified to be key players in this domain:

§  4D Pharma

§  Armata Pharmaceuticals

§  Evelo Biosciences

§  Rebiotix (Acquired by Ferring Pharmaceuticals)

§  Seres Therapeutics

§  Vedanta Biosciences

 

Table of Contents

1.     Preface

 

2.     Executive Summary

 

3.     Introduction

 

4.     Microbiome Therapeutics: Market Landscape

 

5.     Company and Drug Profiles

 

6.     Microbiome Diagnostics: Market Landscape

 

7.     Fecal Microbiota Therapy (FMT)

 

8.     Attractiveness Competitiveness (AC) Matrix

 

9.     Microbiome Related Initiatives of Big Pharmaceutical Players

 

10.  Start-up Health Indexing

 

11.  Key Therapeutics Areas

 

12.  Funding and Investment Analysis

 

13.  Contract Services for Microbiome Therapeutics

 

14.  Big Data and Microbiome Therapeutics

 

15.  Microbiome Therapeutics: Market Forecast and Opportunity Analysis

 

16.  Microbiome Diagnostics: Market Forecast and Opportunity Analysis

 

17.  Fecal Microbiota Therapies: Market Forecast and Opportunity Analysis

 

18.  Case Study: Microbiome-based Products in Other Industries

 

19.  Concluding Remarks

 

20.  Executive Insights

 

21.  Appendix I: Tabulated Data

 

22.  Appendix II: List of Companies and Organizations

 

 

To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/human-microbiome-market/281.html

 

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

[email protected]